Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cd19 universal car-t cells
- Development stage
- Phase 2
- Lead developer
- Allogene Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19 universal CAR-T cells represent an allogeneic cell therapy approach where T cells from healthy donors are engineered with a chimeric antigen receptor (CAR) to specifically target the CD19 protein found on B cells. This 'off-the-shelf' strategy aims to overcome the limitations of autologous CAR-T therapies, such as lengthy manufacturing times, dependence on patient T cell quality, and high costs. The therapy is being investigated for its safety and efficacy in treating CD19-positive refractory/relapsed B-cell malignancies, including B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma, as well as autoimmune diseases like refractory systemic lupus erythematosus, by eliminating pathogenic B cells.
- Other names
- Anti-CD19 Universal CAR-T CellsAnti-CD-19 Universal CAR-T CellsAnti-CD 19 Universal CAR-T Cells
02
Targets
Beyond the preview
Go deeper on cd19 universal car-t cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cd19 universal car-t cells.